Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(4):733–740. doi: 10.1038/sj.bjc.6690756

p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer

G Ferrandina 1, A Fagotti 1, M G Salerno 1, P G Natali 2, M Mottolese 2, F Maneschi 3, A De Pasqua 1, P Benedetti-Panici 3, S Mancuso 1, G Scambia 1
PMCID: PMC2362897  PMID: 10574264

Abstract

The aim of this study was to assess the association of p53 status with primary cytoreduction, response to chemotherapy and outcome in stage III–IV primary ovarian cancer patients. Immunohistochemical analysis of p53 was performed on formalin-fixed, paraffin-embedded specimens from 168 primary ovarian carcinomas by using the DO-7 monoclonal antibody. p53 nuclear positivity was found in 84 out of 162 (52%) malignant tumours. A higher percentage of p53 nuclear positivity was observed in patients with advanced stage of disease than in stage I–II (57% vs 23% respectively; P = 0.0022) and in poorly differentiated versus well/moderately differentiated tumours (59% vs 32% respectively; P = 0.0038). The multivariate analysis aimed to investigate the association of FIGO stage, grade and p53 status with primary cytoreduction in 136 stage III–IV patients showed that stage IV disease may influence the possibility to perform primary cytoreduction in ovarian cancer patients. p53-positivity also maintained a trend to be associated with poor chance of cytoreduction. In patients who underwent pathologic assessment of response, cases who did not respond to chemotherapy were much more frequently p53-positive than p53-negative (86% vs 14% respectively; P = 0.012). Moreover, patients with stage III disease and < 2-cm residual tumour were more likely to respond to treatment. In multivariate analysis, FIGO stage and p53 expression were independently correlated with pathologic response to chemotherapy. Time to progression and survival rates were shown not to be different in p53-positive versus p53-negative patients. © 1999 Cancer Research Campaign

Keywords: p53, ovarian cancer, cytoreduction, response to chemotherapy

Full Text

The Full Text of this article is available as a PDF (188.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodner S. M., Minna J. D., Jensen S. M., D'Amico D., Carbone D., Mitsudomi T., Fedorko J., Buchhagen D. L., Nau M. M., Gazdar A. F. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene. 1992 Apr;7(4):743–749. [PubMed] [Google Scholar]
  2. Bouvet M., Ellis L. M., Nishizaki M., Fujiwara T., Liu W., Bucana C. D., Fang B., Lee J. J., Roth J. A. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 1998 Jun 1;58(11):2288–2292. [PubMed] [Google Scholar]
  3. Bristow R. E., Lagasse L. D., Karlan B. Y. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. Cancer. 1996 Nov 15;78(10):2049–2062. [PubMed] [Google Scholar]
  4. Brown R., Clugston C., Burns P., Edlin A., Vasey P., Vojtesek B., Kaye S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer. 1993 Oct 21;55(4):678–684. doi: 10.1002/ijc.2910550428. [DOI] [PubMed] [Google Scholar]
  5. Buttitta F., Marchetti A., Gadducci A., Pellegrini S., Morganti M., Carnicelli V., Cosio S., Gagetti O., Genazzani A. R., Bevilacqua G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer. 1997;75(2):230–235. doi: 10.1038/bjc.1997.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Diebold J., Baretton G., Felchner M., Meier W., Dopfer K., Schmidt M., Löhrs U. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol. 1996 Mar;105(3):341–349. doi: 10.1093/ajcp/105.3.341. [DOI] [PubMed] [Google Scholar]
  7. Dong Y., Walsh M. D., McGuckin M. A., Cummings M. C., Gabrielli B. G., Wright G. R., Hurst T., Khoo S. K., Parsons P. G. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer. 1997 Aug 22;74(4):407–415. doi: 10.1002/(sici)1097-0215(19970822)74:4<407::aid-ijc8>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  8. Eccles D. M., Brett L., Lessells A., Gruber L., Lane D., Steel C. M., Leonard R. C. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer. 1992 Jan;65(1):40–44. doi: 10.1038/bjc.1992.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Geisler J. P., Geisler H. E., Wiemann M. C., Givens S. S., Zhou Z., Miller G. A. Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol. 1997 Sep;66(3):435–438. doi: 10.1006/gyno.1997.4799. [DOI] [PubMed] [Google Scholar]
  10. Gjerset R. A., Turla S. T., Sobol R. E., Scalise J. J., Mercola D., Collins H., Hopkins P. J. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog. 1995 Dec;14(4):275–285. doi: 10.1002/mc.2940140408. [DOI] [PubMed] [Google Scholar]
  11. Hartmann L. C., Podratz K. C., Keeney G. L., Kamel N. A., Edmonson J. H., Grill J. P., Su J. Q., Katzmann J. A., Roche P. C. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 1994 Jan;12(1):64–69. doi: 10.1200/JCO.1994.12.1.64. [DOI] [PubMed] [Google Scholar]
  12. Henriksen R., Strang P., Wilander E., Bäckström T., Tribukait B., Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol. 1994 Jun;53(3):301–306. doi: 10.1006/gyno.1994.1138. [DOI] [PubMed] [Google Scholar]
  13. Herod J. J., Eliopoulos A. G., Warwick J., Niedobitek G., Young L. S., Kerr D. J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996 May 1;56(9):2178–2184. [PubMed] [Google Scholar]
  14. Klemi P. J., Pylkkänen L., Kiilholma P., Kurvinen K., Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer. 1995 Oct 1;76(7):1201–1208. doi: 10.1002/1097-0142(19951001)76:7<1201::aid-cncr2820760716>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  15. Kohler M. F., Kerns B. J., Humphrey P. A., Marks J. R., Bast R. C., Jr, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol. 1993 May;81(5 ):643–650. [PubMed] [Google Scholar]
  16. Kupryjańczyk J., Bell D. A., Yandell D. W., Scully R. E., Thor A. D. p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol. 1994 Nov;102(5):671–676. doi: 10.1093/ajcp/102.5.671. [DOI] [PubMed] [Google Scholar]
  17. Kupryjańczyk J., Thor A. D., Beauchamp R., Merritt V., Edgerton S. M., Bell D. A., Yandell D. W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961–4965. doi: 10.1073/pnas.90.11.4961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Levesque M. A., Katsaros D., Yu H., Zola P., Sismondi P., Giardina G., Diamandis E. P. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer. 1995 Mar 15;75(6):1327–1338. doi: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  20. Marks J. R., Davidoff A. M., Kerns B. J., Humphrey P. A., Pence J. C., Dodge R. K., Clarke-Pearson D. L., Iglehart J. D., Bast R. C., Jr, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 1991 Jun 1;51(11):2979–2984. [PubMed] [Google Scholar]
  21. Marx D., Meden H., Ziemek T., Lenthe T., Kuhn W., Schauer A. Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer. 1998 May;34(6):845–850. doi: 10.1016/s0959-8049(97)10169-1. [DOI] [PubMed] [Google Scholar]
  22. Michieli P., Chedid M., Lin D., Pierce J. H., Mercer W. E., Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994 Jul 1;54(13):3391–3395. [PubMed] [Google Scholar]
  23. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992 Jun 26;69(7):1237–1245. doi: 10.1016/0092-8674(92)90644-r. [DOI] [PubMed] [Google Scholar]
  24. Perego P., Giarola M., Righetti S. C., Supino R., Caserini C., Delia D., Pierotti M. A., Miyashita T., Reed J. C., Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996 Feb 1;56(3):556–562. [PubMed] [Google Scholar]
  25. Peter A., Heintz M. Surgery in ovarian cancer: the concept of cytoreductive surgery. Curr Opin Obstet Gynecol. 1996 Feb;8(1):8–11. [PubMed] [Google Scholar]
  26. Potter M. E., Partridge E. E., Hatch K. D., Soong S. J., Austin J. M., Shingleton H. M. Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol. 1991 Mar;40(3):195–200. doi: 10.1016/0090-8258(90)90277-r. [DOI] [PubMed] [Google Scholar]
  27. Reles A., Schmider A., Press M. F., Schönborn I., Friedmann W., Huber-Schumacher S., Strohmeyer T., Lichtenegger W. Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol. 1996;122(8):489–494. doi: 10.1007/BF01187161. [DOI] [PubMed] [Google Scholar]
  28. Righetti S. C., Della Torre G., Pilotti S., Ménard S., Ottone F., Colnaghi M. I., Pierotti M. A., Lavarino C., Cornarotti M., Oriana S. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996 Feb 15;56(4):689–693. [PubMed] [Google Scholar]
  29. Röhlke P., Milde-Langosch K., Weyland C., Pichlmeier U., Jonat W., Löning T. p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin Oncol. 1997;123(9):496–501. doi: 10.1007/BF01192204. [DOI] [PubMed] [Google Scholar]
  30. Scambia G., Benedetti-Panici P., Ferrandina G., Distefano M., Salerno G., Romanini M. E., Fagotti A., Mancuso S. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer. 1995 Aug;72(2):361–366. doi: 10.1038/bjc.1995.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Werness B. A., Jobe J. S., DiCioccio R. A., Piver M. S. Expression of the p53 induced tumor suppressor p21waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int J Gynecol Pathol. 1997 Apr;16(2):149–155. doi: 10.1097/00004347-199704000-00011. [DOI] [PubMed] [Google Scholar]
  32. van der Zee A. G., Hollema H., Suurmeijer A. J., Krans M., Sluiter W. J., Willemse P. H., Aalders J. G., de Vries E. G. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol. 1995 Jan;13(1):70–78. doi: 10.1200/JCO.1995.13.1.70. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES